PFS and EFS. Deaths from any cause and transformation to accelerated/blastic phase disease were considered events for PFS calculations. For EFS, events included deaths, progression beyond CP-CML, loss of response, and trial discontinuation for any reason. Two-year PFS (A) and EFS (B) were 98.9% (95% CI, 96.8%-100%) and 85.3% (95% CI, 75.7%-91.4%), respectively.